Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11606MR)

This product GTTS-WQ11606MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11606MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13538MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ15796MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ13573MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ744MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ11047MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ13120MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ1104MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ10038MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW